{"id":"NCT02862171","sponsor":"International Partnership for Microbicides, Inc.","briefTitle":"To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women","officialTitle":"A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-12","primaryCompletion":"2019-01-11","completion":"2019-01-11","firstPosted":"2016-08-10","resultsPosted":"2022-10-25","lastUpdate":"2022-10-25"},"enrollment":941,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["HIV Prevention"],"interventions":[{"type":"DRUG","name":"Dapivirine Vaginal Ring-004","otherNames":["TMC-120"]}],"arms":[{"label":"Dapivirine Vaginal Ring-004","type":"EXPERIMENTAL"}],"summary":"A follow-on, open label trial to assess continued safety of and adherence to the Dapivirine(25mg) vaginal ring-004 in healthy, HIV-negative women","primaryOutcome":{"measure":"The Safety Profile of the 25 mg Dapivirine Vaginal Ring-004, When Inserted at Monthly Intervals. Participants Attended RC at Monthly Visits (up to Max of Three Monthly Visits) Followed by 3-monthly Follow-up Visits.","timeFrame":"at least 12 months and up to 17 months","effectByArm":[{"arm":"Dapivirine Vaginal Ring-004","deltaMin":616,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["South Africa","Uganda"]},"refs":{"pmids":["36345569","33539761"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":941},"commonTop":["Infections","Reproductive system","Headache","Gastritis","Back pain"]}}